Product Information
PYRAZINAMIDE 500 MG TABLET is a generic product labeled by Macleods Pharmaceuticals Limited, priced at $1.3081 per EA under NDC 33342044711. Its NADAC has been published 181 times since Oct 19, 2022.
FDA first approved this application on Jul 27, 2020. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
500 mg/1
Manufacturer
Macleods Pharmaceuticals LimitedNDC
33342044711
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PYRAZINAMIDEApproval Type
Generic (ANDA)
FDA Application
ANDA212541FDA Approved
7/27/2020
TE Code
AB
On Market Since
7/27/2020
Pharmacological Classes
Price Statistics
The NADAC for PYRAZINAMIDE 500 MG TABLET has been published 181 times since Oct 19, 2022, and over the history we have for it it has declined 53.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.3081 per EA |
|---|---|
| All-time high | $2.8316 (Oct 11, 2023) |
| All-time low | $1.3081 (Sep 23, 2026) |
| 52-week high | $2.3801 |
| 52-week low | $1.3081 |
| Median price | $2.4789 |
| Average price | $2.3656 |
| Largest weekly change | -19.3% (Jul 17, 2024) |
| Weeks tracked | 181 |
| Tracking since | Oct 19, 2022 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Macleods Pharmaceuticals Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Pyrazinamide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Antimycobacterial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PYRAZINAMIDE 500 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for PYRAZINAMIDE 500 MG TABLET, manufactured by Macleods Pharmaceuticals Limited, is $1.3081 per EA (NDC 33342044711), effective Sep 30, 2026.
How has the price of PYRAZINAMIDE 500 MG TABLET changed over time?
Over the history we have for it, the NADAC for PYRAZINAMIDE 500 MG TABLET has declined 53.8%. It has been tracked across 181 weekly CMS publications since Oct 19, 2022.
What are the highest and lowest recorded NADAC prices for PYRAZINAMIDE 500 MG TABLET?
Since Oct 19, 2022, the NADAC for PYRAZINAMIDE 500 MG TABLET has ranged from a low of $1.3081 (Sep 23, 2026) to a high of $2.8316 (Oct 11, 2023), with a median of $2.4789 per EA.
Are there cheaper alternatives to PYRAZINAMIDE 500 MG TABLET?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as PYRAZINAMIDE 500 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures PYRAZINAMIDE 500 MG TABLET?
PYRAZINAMIDE 500 MG TABLET (NDC 33342044711) is labeled by Macleods Pharmaceuticals Limited, and CMS classifies it as a generic product.